Journal
VACCINE
Volume 27, Issue 12, Pages 1869-1874Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.12.061
Keywords
Hepatitis E; HEV; HEV vaccine; Clinical trial
Categories
Funding
- Ministry of Science and Technology of the People's Republic of China [2005DFA30820, 2006AA02A209]
- Fujian Provincial Department of Sciences and Technology [2004YZ01]
- Xiamen Science And Technology Bureau [3502Z20041008]
Ask authors/readers for more resources
The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis F. virus (HEV). The safety and immunogenicity of the vaccine for humans was assessed in a randomized controlled phase II clinical trial. The study was conducted in an endemic area of southern China and consisted of a dose scheduling, involving 457 adults and a dose escalation component involving 155 high school students. The results showed that the vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
